Top 5 Stocks to Buy Now
→ This Startup is Growing 23X Faster than Nvidia (From Brownstone Research) (Ad)tc pixel Free DXR Stock Alerts

Daxor (DXR) Competitors

Daxor logo
$10.14 +0.64 (+6.74%)
As of 06/23/2026 03:27 PM Eastern
Compare

DXR vs. TLSI, SMTI, LUCD, PDEX, and APYX

Should you buy Daxor stock or one of its competitors? MarketBeat compares Daxor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Daxor include TriSalus Life Sciences (TLSI), Sanara MedTech (SMTI), Lucid Diagnostics (LUCD), Pro-Dex (PDEX), and Apyx Medical (APYX). These companies are all part of the "medical equipment" industry.

How does Daxor compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

TriSalus Life Sciences presently has a consensus price target of $7.50, indicating a potential upside of 86.10%. Given TriSalus Life Sciences' higher possible upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-60.85% N/A -69.91%
Daxor N/A N/A N/A

TriSalus Life Sciences has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$45.15M5.48-$39.23M-$1.41N/A
Daxor$10.30M5.75N/AN/AN/A

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 1 mentions for Daxor. TriSalus Life Sciences' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Daxor
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TriSalus Life Sciences beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Sanara MedTech?

Daxor (NASDAQ:DXR) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, Sanara MedTech had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Sanara MedTech and 1 mentions for Daxor. Sanara MedTech's average media sentiment score of 1.78 beat Daxor's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Daxor
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sanara MedTech
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Daxor has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Daxor has higher earnings, but lower revenue than Sanara MedTech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Daxor$10.30M5.75N/AN/AN/A
Sanara MedTech$103.12M1.93-$37.56M-$3.77N/A

1.3% of Daxor shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 51.5% of Daxor shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Daxor's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Sanara MedTech -31.23%-3.19%-0.56%

Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 56.32%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts clearly believe Sanara MedTech is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Sanara MedTech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Summary

Sanara MedTech beats Daxor on 9 of the 14 factors compared between the two stocks.

How does Daxor compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Lucid Diagnostics presently has a consensus price target of $4.19, indicating a potential upside of 306.55%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, research analysts plainly believe Lucid Diagnostics is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Daxor has higher revenue and earnings than Lucid Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucid Diagnostics$4.71M44.41-$58.01M-$0.47N/A
Daxor$10.30M5.75N/AN/AN/A

Daxor has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%.

Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics-876.72% N/A -116.26%
Daxor N/A N/A N/A

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Daxor had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 1 mentions for Daxor and 0 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company Overall Sentiment
Lucid Diagnostics Neutral
Daxor Neutral

Summary

Lucid Diagnostics beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Pro-Dex has higher revenue and earnings than Daxor.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Daxor$10.30M5.75N/AN/AN/A
Pro-Dex$66.59M3.04$8.98M$3.6217.51

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Pro-Dex 16.08%22.78%14.30%

Daxor has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

1.3% of Daxor shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pro-Dex had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Daxor
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pro-Dex
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 10.43%. Given Pro-Dex's higher probable upside, analysts clearly believe Pro-Dex is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Pro-Dex
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Pro-Dex beats Daxor on 7 of the 11 factors compared between the two stocks.

How does Daxor compare to Apyx Medical?

Daxor (NASDAQ:DXR) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Daxor has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Daxor has a net margin of 0.00% compared to Apyx Medical's net margin of -16.40%. Daxor's return on equity of 0.00% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Apyx Medical -16.40%-88.47%-14.94%

In the previous week, Apyx Medical had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Apyx Medical and 1 mentions for Daxor. Apyx Medical's average media sentiment score of 1.05 beat Daxor's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Daxor
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apyx Medical
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

1.3% of Daxor shares are owned by institutional investors. Comparatively, 55.3% of Apyx Medical shares are owned by institutional investors. 51.5% of Daxor shares are owned by company insiders. Comparatively, 15.2% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Daxor has higher earnings, but lower revenue than Apyx Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Daxor$10.30M5.75N/AN/AN/A
Apyx Medical$55.90M3.06-$11.21M-$0.22N/A

Apyx Medical has a consensus price target of $6.50, indicating a potential upside of 59.31%. Given Apyx Medical's stronger consensus rating and higher possible upside, analysts clearly believe Apyx Medical is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Apyx Medical beats Daxor on 9 of the 14 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXR vs. The Competition

Export
MetricDaxorMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.46M$5.72B$6.44B$12.30B
Dividend YieldN/A1.57%2.69%5.83%
P/E RatioN/A36.4924.6623.99
Price / Sales5.7525.65531.91108.06
Price / CashN/A16.9844.8254.51
Price / BookN/A3.2710.816.50
Net IncomeN/A$218.81M$3.56B$336.88M
7 Day Performance3.21%2.60%0.93%-0.16%
1 Month Performance-4.11%3.26%0.35%0.76%
1 Year Performance9.15%17.73%29.69%28.49%

Daxor Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
2.1938 of 5 stars		$10.14
+6.7%		N/A+7.2%$55.46M$10.30MN/A37
TLSI
TriSalus Life Sciences
2.9412 of 5 stars		$3.64
+2.5%		$7.50
+106.0%		-23.8%$218.03M$45.15MN/A106
SMTI
Sanara MedTech
2.663 of 5 stars		$21.50
-6.5%		$34.00
+58.1%		-21.8%$210.68M$103.12MN/A60
LUCD
Lucid Diagnostics
4.0444 of 5 stars		$0.98
-3.2%		$4.19
+328.1%		-13.4%$198.62M$5.13MN/A70
PDEX
Pro-Dex
2.1189 of 5 stars		$62.92
+1.5%		$70.00
+11.3%		+51.6%$197.89M$66.59M17.38140

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Four winners over 400%. Here's #5
CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...
Golden Portfolio | Sponsoredtc pixel
25-Cent Gold Explorer Set to Drill Top Canadian Mineral Belt
With gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign o...
Resource Stock Digest | Sponsoredtc pixel
My feud with Zohran Mamdani
Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...
Stansberry Research | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This
Elon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...
Brownstone Research | Sponsoredtc pixel